TerminatedPhase 3NCT04197986
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Studying Upper tract urothelial carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QED Therapeutics, a BridgeBio company
- Principal Investigator
- David van Veenhuyzen, M.B., Ch.B., M.Pharm.Med.QED Therapeutics, a BridgeBio company
- Intervention
- Infigratinib(drug)
- Enrollment
- 39 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (30)
- Arizona Oncology Associates, Tucson, Arizona, United States
- City of Hope - Duarte, Duarte, California, United States
- City of Hope, Duarte, California, United States
- Loma Linda University Faculty Medical Clinics, Loma Linda, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- The Urology Center of Colorado, Denver, Colorado, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Urological Research Network CORP, Hialeah, Florida, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- UChicago Medicine Duchossois Center for Advanced Medicine (DCAM) - Hyde Park, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Helsinn Healthcare SA
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04197986 on ClinicalTrials.govOther trials for Upper tract urothelial carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07452432Korean Prospective Upper Tract Urothelial Carcinoma CohortSamsung Medical Center
- RECRUITINGNANCT07321210Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical TrialTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc
- RECRUITINGPHASE2NCT07225374Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCSamsung Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07492225Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized TrialChanghai Hospital
- RECRUITINGPHASE2NCT06356155Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial CancerUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT07126119Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCTianjin Medical University Second Hospital
- RECRUITINGPHASE1NCT06848868Ambulatory Flexible URS for UTUC SurveillanceChinese University of Hong Kong